Market Cap
$586.9M
VALN
Valneva SE
$5.80 ▼ -1.68%
Prev close $5.90Market cap$586.9M
12-mo target$12.25 (+111.2%)
3 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on VALN right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
8 funds
Inst. Value
$1.5M
Inst. Activity
3 buys / 0 sells
Social Sentiment
67° Warm
SEC Reports
5
Price chart 30d -18.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 17, 2026 ftd
FTD: VALN — 76,834 shares ($0.5M) failed to deliver
Settlement: 20260817, Price: $7.13, FTD Value: $547,826.42, VALNEVA SE SPONSORED ADS (FRA)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
4,525 shares ($23.7K)
Jun 30, 2026 Inst.
Jun 17, 2026 SEC BNP PARIBAS FINANCIAL MARKETS — DOUBLED
559 shares ($2.9K)
Valneva SE's SEC registration statement (F-3, File No. 333-296504) became effective as of June 16, 2026, allowing the co
EFFECT — Impact 3/10
Valneva filed a 6-K announcing the availability of documentation for its Annual General Meeting scheduled for June 25, 2
6-K — Impact 2/10
Valneva announced participation in investor conferences (Jefferies, Oddo BHF, BNP Paribas) and a travel medicine confere
6-K — Impact 2/10
Analyst ratings buy % +1.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2025 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 25, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 8, 2025 | Guggenheim | MAINTAIN | Buy | 52% |
| Apr 15, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 9, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 2, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Mar 31, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Mar 24, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Mar 24, 2025 | Guggenheim | MAINTAIN | Buy | 52% |
| Mar 21, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 6 | 1 | 1 | 0 | 83% | |
| Aug 1, 2026 | 4 | 6 | 1 | 1 | 0 | 83% | |
| Jul 1, 2026 | 4 | 6 | 1 | 1 | 0 | 83% | |
| Jun 1, 2026 | 4 | 6 | 1 | 1 | 0 | 83% | |
| May 1, 2026 | 4 | 6 | 1 | 1 | 0 | 83% | |
| Apr 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% |
Price targets
Where 4 covering analysts think VALN trades over the next 12 months.
$12.25 +111.2% upside Strong Buy
Current$5.80 Low$5.00 Median$13.00 High$18.00 4 analysts
$5.00$18.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 5 neutral · avg impact 2.4/10.
NEUTRALEFFECT3/10
Valneva SE's SEC registration statement (F-3, File No. 333-296504) became effective as of June 16, 2
Jun 17, 2026
NEUTRAL6-K2/10
Valneva filed a 6-K announcing the availability of documentation for its Annual General Meeting sche
Jun 5, 2026
NEUTRAL6-K2/10
Valneva announced participation in investor conferences (Jefferies, Oddo BHF, BNP Paribas) and a tra
Jun 1, 2026
NEUTRAL6-K2/10
Valneva announced it will report Q1 2026 financial results on May 13, 2026. The press release contai
May 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 25, 2026
Clinical Trial
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
Phase Phase 2 — COMPLETED
Aug 17, 2026
ftd
FTD: VALN — 76,834 shares ($0.5M) failed to deliver
Settlement: 20260817, Price: $7.13, FTD Value: $547,826.42, VALNEVA SE SPONSORED ADS (FRA)
Jun 4, 2026
Clinical Trial
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.01 | $0.01–$0.01 | 101.7% | +107.7% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $0.07 | $0.07–$0.07 | 110.7% | +275.0% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-1.13 | $-1.13–$-1.13 | 27.4% | +8.1% | 1↑ 0↓ | $0.2B | 1 |
| Next FY | $1.19 | $1.19–$1.19 | 205.3% | +14.4% | 1↑ 0↓ | $0.3B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.010 | — |
| 7d ago | $-0.130 | +0.140 |
| 30d ago | $-0.130 | +0.140 |
| 60d ago | $-0.130 | +0.140 |
| 90d ago | $-0.130 | +0.140 |
Institutional ownership
Which big funds own VALN (from quarterly 13F filings) and who is adding or trimming.
8 institutional holders with $1.5M total value (295,982 shares) as of 2026-Q2. Top holders: MILLENNIUM, WELLS, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 135,223 | $707.2K | 45.7% | — |
| WELLS FARGO & COMPANY/MN | 77,214 | $403.8K | 26.1% | TRIM -36.8% |
| MORGAN STANLEY | 56,217 | $294.0K | 19.0% | ADD +30.3% |
| CITADEL ADVISORS LLC | 20,294 | $106.1K | 6.9% | TRIM -54.1% |
| UBS Group AG | 4,525 | $23.7K | 1.5% | DOUBLED +478.6% |
| RHUMBLINE ADVISERS | 1,860 | $9.7K | 0.6% | DOUBLED +708.7% |
| BNP PARIBAS FINANCIAL MARKETS | 559 | $2.9K | 0.2% | DOUBLED +179.5% |
| OSAIC HOLDINGS, INC. | 90 | $471.00 | 0.0% | ADD +63.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 782 | 4,525 | +478.6% | $23.7K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 200 | 559 | +179.5% | $2.9K |
| OSAIC HOLDINGS, INC. | ADD | 55 | 90 | +63.6% | $471.00 |
| WELLS FARGO & COMPANY/MN | TRIM | 123,463 | 78,029 | -36.8% | $487.7K |
| UBS Group AG | DOUBLED | 203 | 782 | +285.2% | $4.9K |
| OSAIC HOLDINGS, INC. | NEAR_EXIT | 1,555 | 55 | -96.5% | $344.00 |
| MORGAN STANLEY | ADD | 32,987 | 42,981 | +30.3% | $379.1K |
| RHUMBLINE ADVISERS | DOUBLED | 218 | 1,763 | +708.7% | $15.5K |
| OSAIC HOLDINGS, INC. | DOUBLED | 555 | 1,555 | +180.2% | $13.7K |
| UBS Group AG | TRIM | 472 | 203 | -57.0% | $1.8K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VALN.
Shares short
191,759
Settlement Sep 15, 2026
Change vs prior
-1.2%
Semi-monthly cycle
Days to cover
4.8
At avg daily volume
Of shares outstanding
≈0.2%
Estimate — not % of float
All VALN filing & press-release reports (5)
- EFFECT reportJun 17, 2026
- 6-K reportJun 5, 2026
- 6-K reportJun 1, 2026
- 6-K reportMay 5, 2026
- 6-K reportMar 26, 2026